#United States #New York #Class Action #Pomerantz Law Firm #Unicycive Therapeutics

Pomerantz Law Firm Initiates Class Action Against Unicycive Therapeutics

On September 18, 2025, Pomerantz LLP announced the filing of a class action lawsuit against Unicycive Therapeutics, Inc., along with specific company officers. This legal action, recorded in the United States District Court, Northern District of California, is aimed at protecting investors who acquired Unicycive securities between March 29, 2024, and June 27, 2025, a period crucial for the allegations outlined in the suit.

The class action, cited under docket number 25-cv-06923, has been prepared on behalf of all individuals and entities, excluding the Defendants, who made purchases or acquired Unicycive securities within the stated timeframe. The plaintiffs seek to recover damages resulting from alleged violations of the federal securities laws as stipulated under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, along with Rule 10b-5 issued by the Securities and Exchange Commission (SEC).

Steps for Affected Investors

Investors who purchased or otherwise secured Unicycive securities during the Class Period have a key deadline approaching. They must file a request with the Court to be appointed as Lead Plaintiff by October 14, 2025. Relevant documents, including the lawsuit's complaint, are available on the Pomerantz Law Firm's website (www.pomerantzlaw.com). Collaboration inquiries regarding this matter can be directed to attorney Danielle Peyton at [email protected] or through the toll-free hotline 888.4-POMLAW, extension 7980.

Background on Unicycive and Allegations

Unicycive, which trades under the NASDAQ symbol UNCY, is positioned as a clinical-stage biotechnology firm that crafts therapies aimed at unmet medical needs in the U.S. Among its notable developments is oxylanthanum carbonate (OLC), a proposed treatment intended for managing hyperphosphatemia in chronic kidney disease (CKD) patients on dialysis.

Throughout the class action period, Unicycive's executives allegedly oversold the readiness and capability of their submissions for a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) concerning OLC. These claims were made under the notion of meeting strict manufacturing compliance standards set forth by the agency.

The situation escalated in September 2024, marking the submission of the OLC NDA to the FDA. However, the complaint contends that this readiness was grossly overstated, coupled with assertions that the NDA's prospects were misrepresented. These misleading statements made by Unicycive's executives potentially misled investors about the actual state of the company’s operations and compliance policies.

In a shocking turn of events, on June 10, 2025, Unicycive revealed that the FDA had flagged deficiencies concerning current good manufacturing practice (cGMP) compliance at a third-party vendor employed for their drug production. This news led to a dramatic drop in Unicycive's stock price, plummeting 40.89% in one day.

Subsequently, on June 30, 2025, the situation worsened when Unicycive announced that the FDA had issued a Complete Response Letter (CRL) regarding the OLC NDA, reinforcing the previously identified deficiencies. Following this revelation, the stock tumbled further, closing a staggering 29.85% lower by day's end.

The Pomerantz Legacy

Pomerantz LLP has a strong reputation as a leader in corporate and securities class litigation. With over 85 years of experience, the firm was founded by Abraham L. Pomerantz, often viewed as the pioneer of class action suits. The firm has been pivotal in recovering substantial damages for victims of securities fraud and corporate misconduct, continually combating such injustices in the financial world. Interested investors are recommended to visit their official site for more information and updates on the ongoing matter.

Attorney advertising materials remind potential clients that past results do not predict similar outcomes. For any further questions or assistance, contact details for the Pomerantz Law Firm are provided, ensuring that victims of these alleged injustices have a pathway for seeking redress.